Serotonin 5-HT3 Receptor Antagonists
"Serotonin 5-HT3 Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that bind to but do not activate SEROTONIN 5-HT3 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT3 RECEPTOR AGONISTS.
| Descriptor ID |
D058831
|
| MeSH Number(s) |
D27.505.519.625.850.850.300 D27.505.696.577.850.850.300
|
| Concept/Terms |
Serotonin 5-HT3 Receptor Antagonists- Serotonin 5-HT3 Receptor Antagonists
- Serotonin 5 HT3 Receptor Antagonists
- 5-HT3 Antagonist
- 5 HT3 Antagonist
- Antagonist, 5-HT3
- 5-HT3 Antagonists
- 5 HT3 Antagonists
- Antagonists, 5-HT3
|
Below are MeSH descriptors whose meaning is more general than "Serotonin 5-HT3 Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Serotonin 5-HT3 Receptor Antagonists".
This graph shows the total number of publications written about "Serotonin 5-HT3 Receptor Antagonists" by people in this website by year, and whether "Serotonin 5-HT3 Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 2 | 3 |
| 2007 | 2 | 1 | 3 |
| 2009 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Serotonin 5-HT3 Receptor Antagonists" by people in Profiles.
-
Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis. Crit Rev Oncol Hematol. 2019 Oct; 142:164-186.
-
Molecular mechanism of setron-mediated inhibition of full-length 5-HT3A receptor. Nat Commun. 2019 07 19; 10(1):3225.
-
Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Support Care Cancer. 2018 Aug; 26(8):2519-2549.
-
Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients. Paediatr Drugs. 2017 Jun; 19(3):213-222.
-
Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Apr 07; 374(14):1356-67.
-
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Eur J Cancer. 2016 Apr; 57:23-30.
-
5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochim Biophys Acta. 2015 Oct; 1848(10 Pt B):2738-46.
-
Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2014 Dec; 15(17):2599-608.
-
Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents. Drugs. 2013 Mar; 73(3):249-62.
-
Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist. Expert Opin Drug Metab Toxicol. 2009 Dec; 5(12):1577-86.